ANI Pharmaceuticals Says Phase 4 ILUVIEN Trial In Chronic Posterior Uveitis Met Co-Primary Endpoints, Results Maintained At 24 Months
Share
Why It Matters
ANI Pharmaceuticals tested a medicine for eye inflammation. The medicine worked well and kept working over two years.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.